These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20966546)

  • 1. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
    Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
    Anal Cell Pathol (Amst); 2010; 33(2):95-104. PubMed ID: 20966546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
    Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
    Cell Oncol (Dordr); 2011 Jun; 34(3):215-23. PubMed ID: 21717218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on 16p13.3 Locus in Colon Cancer.
    Mampaey E; Fieuw A; Van Laethem T; Ferdinande L; Claes K; Ceelen W; Van Nieuwenhove Y; Pattyn P; De Man M; De Ruyck K; Van Roy N; Geboes K; Laurent S
    PLoS One; 2015; 10(7):e0131421. PubMed ID: 26222184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
    van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
    Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of chromosome 18q microsatellite alterations in stage II colonic carcinoma.
    Wang W; Wang GQ; Sun XW; Chen G; Li YF; Zhang LY; Qiu HB; Huang CY; Zhan YQ; Zhou ZW
    World J Gastroenterol; 2010 Dec; 16(47):6026-34. PubMed ID: 21157981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
    Watanabe T; Wu TT; Catalano PJ; Ueki T; Satriano R; Haller DG; Benson AB; Hamilton SR
    N Engl J Med; 2001 Apr; 344(16):1196-206. PubMed ID: 11309634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients.
    Wang W; Li YF; Sun XW; Chen G; Zhan YQ; Huang CY; Wan DS; Pan ZZ; Zhou ZW
    Chin J Cancer; 2010 Aug; 29(8):761-7. PubMed ID: 20663324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer.
    Sefrioui D; Vermeulin T; Blanchard F; Chapusot C; Beaussire L; Armengol-Debeir L; Sesboué R; Gangloff A; Hebbar M; Copin MC; Houivet E; Schwarz L; Clatot F; Tuech JJ; Bénichou J; Martin L; Bouvier AM; Sabourin JC; Sarafan-Vasseur N; Frébourg T; Lepage C; Michel P; Di Fiore F
    Int J Cancer; 2017 Apr; 140(7):1653-1661. PubMed ID: 28006840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer.
    Mayrhofer M; Kultima HG; Birgisson H; Sundström M; Mathot L; Edlund K; Viklund B; Sjöblom T; Botling J; Micke P; Påhlman L; Glimelius B; Isaksson A
    BMC Cancer; 2014 Nov; 14():872. PubMed ID: 25420937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer.
    Lanza G; Matteuzzi M; Gafá R; Orvieto E; Maestri I; Santini A; del Senno L
    Int J Cancer; 1998 Aug; 79(4):390-5. PubMed ID: 9699532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candidate driver genes in focal chromosomal aberrations of stage II colon cancer.
    Brosens RP; Haan JC; Carvalho B; Rustenburg F; Grabsch H; Quirke P; Engel AF; Cuesta MA; Maughan N; Flens M; Meijer GA; Ylstra B
    J Pathol; 2010 Aug; 221(4):411-24. PubMed ID: 20593488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
    Donada M; Bonin S; Nardon E; De Pellegrin A; Decorti G; Stanta G
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):201-10. PubMed ID: 20387074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
    Chouhan H; Sammour T; Thomas ML; Moore JW
    J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator.
    Ogunbiyi OA; Goodfellow PJ; Herfarth K; Gagliardi G; Swanson PE; Birnbaum EH; Read TE; Fleshman JW; Kodner IJ; Moley JF
    J Clin Oncol; 1998 Feb; 16(2):427-33. PubMed ID: 9469325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell cycle proteins predict recurrence in stage II and III colon cancer.
    Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
    Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
    J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
    Bertagnolli MM; Redston M; Compton CC; Niedzwiecki D; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS
    J Clin Oncol; 2011 Aug; 29(23):3153-62. PubMed ID: 21747089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
    Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
    J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
    Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A
    Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.